title: Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome.
abstract: OBJECTIVE
  To evaluate the effectiveness of sibutramine therapy alone and in combination with ethinyl estradiol-cyproterone acetate (EE-CPA) on the clinical and metabolic parameters of obese women with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Prospective randomized, controlled study.
  
  
  METHODS
  Endocrinology and gynecology clinics.
  
  
  METHODS
  Forty obese women with PCOS.
  
  
  METHODS
  Group 1 was treated with oral EE-CPA (35 microg-2 mg/day), group 2 with oral sibutramine (10 mg/day), and group 3 with a combination of EE-CPA plus sibutramine for 6 months. All groups were advised to consume a diet of 1200 kcal/day.
  
  
  METHODS
  Measurements were performed before and 6 months after treatment of body mass index, waist-to-hip ratio, systolic and diastolic blood pressure, Ferriman-Gallwey hirsutism score, total testosterone, free testosterone, sex hormone-binding globulin, dihydroepiandrosterone sulfate (DHEAS), total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, glucose and insulin during oral glucose tolerance test, and insulin sensitivity index; area under the curve for glucose and insulin were obtained from OGTT.
  
  
  RESULTS
  Body mass index, Ferriman-Gallwey hirsutism score, serum total testosterone, free testosterone, and DHEAS levels were significantly decreased and SHBG was significantly increased in all groups at the end of the study. WHR, diastolic blood pressure, and serum triglyceride level were significantly reduced only in the sibutramine group.
  
  
  CONCLUSIONS
  Sibutramine might have a positive effect on hyperandrogenemia, and clinical and metabolic risk factors for cardiovascular disease in obese women with PCOS.
authors: Endocrinology and Metabolism Department, University of Harran, Faculty of Medicine, Sanliurfa, Turkey. sabuncu@ixir.com
authors: Tevfik
authors: T
authors: Sabuncu
authors: Muge
authors: M
authors: Harma
authors: Mehmet
authors: M
authors: Harma
authors: Yasar
authors: Y
authors: Nazligul
authors: Feryal
authors: F
authors: Kilic
mesh_terms: D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use*; D001794:Blood Pressure; D001824:Body Constitution; D001835:Body Weight / Q000187:drug effects; D003503:Cyclobutanes / Q000627:therapeutic use*; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D003971:Diastole; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D006628:Hirsutism / Q000209:etiology; D006728:Hormones / Q000097:blood; D006801:Humans; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000188:drug therapy; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D000726:Androgen Antagonists; D001067:Appetite Depressants; D003503:Cyclobutanes; D004338:Drug Combinations; D006728:Hormones; D014280:Triglycerides; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C058254:sibutramine